Market revenue in 2023 | USD 23.3 million |
Market revenue in 2030 | USD 235.9 million |
Growth rate | 39.2% (CAGR from 2023 to 2030) |
Largest segment | C.difficle |
Fastest growing segment | C.difficle |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C.difficle, Crohns disease, IBS, Diabetes |
Key market players worldwide | Carbios SA, Boise Cascade Co, Assembly Biosciences Inc, Wacker Chemie AG, SGS AG, Lonza Group Ltd, Arranta Bio, 4D Pharma, NIZO, Inpac Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to live biotherapeutic products and microbiome cdmo market will help companies and investors design strategic landscapes.
C.difficle was the largest segment with a revenue share of 86.27% in 2023. Horizon Databook has segmented the U.S. live biotherapeutic products and microbiome cdmo market based on c.difficle, crohns disease, ibs, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. accounts for the highest share of North America live biotherapeutic products and microbiome CDMO market as a large number of pharmaceutical and life sciences companies are present in this country.
Growing interest in clinical trials and the benefits of live biotherapeutics for rare diseases are driving the development of new & novel drugs. Moreover, a well-established regulatory framework provides new opportunities for companies to develop and manufacture products with a wide range of applications & target population with improved knowledge of the importance of microbiota in terms of health & disease.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. live biotherapeutic products and microbiome cdmo market , including forecasts for subscribers. This country databook contains high-level insights into U.S. live biotherapeutic products and microbiome cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account